Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial Meeting Abstract
| Authors: | Loriot, Y.; Fizazi, K.; De Bono, J. S.; Forer, D.; Hirmand, M.; Scher, H. I. |
| Abstract Title: | Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419601663 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.5065 |
| Notes: | Meeting Abstract: 5065 -- Source: Wos |
